Multiple sclerosis (MS) is a complex and unpredictable disease that affects the central nervous system, leading to a variety of symptoms. Identifying the early warning signs of multiple sclerosis is very important for seeking prompt treatment and potentially slowing its progression. One of the most promising advancements in MS treatment is stem cell therapy. Stem cell treatments for multiple sclerosis focus on repairing nerve damage, regenerating myelin, and improving overall function. Although still being researched, stem cell therapy for MS has shown promise in reducing symptoms such as muscle weakness, fatigue, and coordination issues. In a clinical trial published in JAMA Neurology, 69% of patients who underwent hematopoietic stem cell transplantation (HSCT) experienced no progression of disability over five years, compared to just 46% in the control group receiving standard disease-modifying therapies (DMTs).
At Stemedix, we specialize in providing advanced stem cell therapies, offering patients personalized care and treatment options. This blog will discuss the potential benefits and limitations of stem cell therapy for MS, helping you determine if it’s the right option for you and how it could enhance your quality of life.
What is Multiple Sclerosis (MS)?
Multiple sclerosis (MS) is a chronic autoimmune condition that affects the central nervous system. It occurs when the immune system mistakenly attacks the myelin sheath, which serves to protect nerve fibers. This damage interferes with communication between the brain and the rest of the body, impacting motor skills, sensory perception, and cognitive functions.
The symptoms of MS can vary widely from one person to another, making early diagnosis difficult. Common early signs of multiple sclerosis include blurred or double vision, unexplained fatigue, and numbness or tingling in the limbs. These symptoms may appear intermittently, which can complicate the identification of the condition in its early stages.
MS can progress differently for each individual. Some people experience flare-ups followed by periods of stability, while others may notice a gradual worsening of symptoms. Identifying early warning signs of multiple sclerosis is important for a timely diagnosis and exploring potential treatments that can help manage symptoms and slow disease progression.
At Stemedix, we recognize the profound impact MS can have on your life. We are dedicated to providing advanced treatment options designed to improve your quality of life. If you are experiencing any of these early warning signs of multiple sclerosis, we encourage you to consult with a healthcare professional and explore treatments that could positively influence your health journey.
What is Stem Cell Therapy for Multiple Sclerosis?
Stem cell therapy for multiple sclerosis (MS) provides a new way to address the challenges of the disease by targeting nerve damage. The main objective of this treatment is to repair the myelin sheath, which safeguards nerve fibers and gets damaged by MS. By repairing this critical tissue, stem cell therapy may help restore lost functions and slow the progression of the disease.
Stem cells are remarkable in their ability to transform into various cell types, including nerve cells. There are two primary types of stem cells used in MS treatment: autologous stem cells, which come from the patient’s own body, and allogeneic stem cells, which are harvested from a healthy donor.
These stem cells are introduced into the patient’s body through a specific process designed to repair the damaged myelin tissue. Additionally, stem cell therapy is believed to help regulate the immune system. Since MS is an autoimmune condition where the immune system attacks the body’s tissues, this function of stem cells is vital in the treatment.
Although stem cell therapy for MS is still considered experimental, it offers the potential for not just repairing nerve damage but also slowing or even stopping the disease’s progression. However, it is important to recognize that it has not yet received approval from regulatory authorities like the FDA.
At Stemedix, we understand the daily challenges of living with MS. Our team is dedicated to offering personalized care to help improve your quality of life and explore potential treatments that may offer a new approach to managing this complex disease.
Potential Benefits of Stem Cell Therapy for MS
Stem cell therapy for multiple sclerosis (MS) offers promising potential for improving the lives of those affected by this chronic condition. While still in the experimental stage, research and clinical studies are showing encouraging results for the benefits this treatment could provide. Below are some of the main advantages stem cell therapy may offer MS patients:
Improvement in Motor Function and Mobility
Stem cell therapy for MS holds great potential in improving motor function and mobility. MS causes nerve damage that interferes with communication between the brain and muscles, leading to issues with coordination, balance, and movement. By repairing the damaged myelin sheath, stem cells can help restore some motor function, resulting in better balance and coordination. This improvement can make it easier for individuals to walk and complete daily activities. Additionally, stem cell treatments may increase the range of motion, offering more independence and reducing the need for assistive devices like canes or walkers.
Reduction in Symptoms of MS
Stem cell therapy has shown potential in helping to manage some of the more challenging symptoms of multiple sclerosis (MS). Symptoms like muscle spasms, numbness, and tingling are often caused by nerve damage. Stem cells may help repair this damage, potentially reducing the severity and frequency of these symptoms. Additionally, stem cell therapy may help alleviate chronic pain and fatigue, which are common in many MS patients, by promoting nerve regeneration. These improvements could make daily activities easier and substantially improve a patient’s overall quality of life.
Slowing Disease Progression
Another benefit of stem cell treatments for multiple sclerosis is its potential to slow or even stop the progression of the disease. A long-term follow-up study found that 44% of patients who received autologous hematopoietic stem cell transplantation (AHSCT) remained free from progression after 10 years, compared to just 16% in those receiving conventional therapies. While stem cell therapy for MS is not a cure, studies indicate they may help prevent further damage to the myelin sheath, which is essential for preventing the neurological decline associated with MS. By stabilizing the condition and limiting additional nerve damage, stem cell therapy could slow the progression of MS, providing long-term benefits. This may allow people with MS to preserve their mobility, cognitive abilities, and overall well-being for a longer time.
Stem cell therapy for MS offers promising potential in enhancing mobility, reducing symptoms, and slowing the progression of the disease. While further research is necessary to determine its long-term impact fully, these possible benefits bring hope to those living with MS. At Stemedix, we focus on providing personalized care and treatment options designed to help manage MS symptoms.
Limitations and Considerations of Stem Cell Therapy for MS
While stem cell therapy for multiple sclerosis (MS) offers potential benefits, it is important to identify the limitations and factors that come with this treatment. Like any medical treatment, stem cell therapy has its challenges. Let’s explore some key considerations that need attention:
Research and FDA Approval Status
While stem cell therapy for MS holds significant promise, it’s important to note that it is still in the experimental stage. Initial research and clinical trials have shown encouraging results, but the treatment has not yet received FDA approval. Since the therapy has not been FDA-approved, there is limited long-term data on its safety and effectiveness. More extensive studies are needed to understand its full potential better. Patients interested in this treatment should be aware that it is still under investigation, and outcomes may vary. However, these early findings suggest a hopeful future for the therapy in managing MS.
Individual Response to Treatment
The results of stem cell treatments for multiple sclerosis can vary for each person. Different factors, such as overall health, the stage of MS, and disease progression, influence how a patient responds to the treatment. For example, people in the early stages of MS may experience greater improvements in mobility and symptom relief than those in later stages. Other factors, like age, immune system function, and existing health conditions, can also affect how effective the therapy is. This is why a thorough evaluation is needed to conclude whether stem cell therapy is the best option for each patient.
Cost and Accessibility
Stem cell treatments for multiple sclerosis may come with costs that can vary depending on the type of treatment and the care needed. These expenses typically include stem cell harvesting, the procedure itself, and any post-treatment care or monitoring. Since stem cell therapy for MS is still considered experimental, many insurance plans may not cover the treatment. However, at Stemedix, we work to make this treatment as accessible as possible. We offer a dedicated care coordinator to help you understand both the potential benefits and costs. Additionally, we provide guidance on financing options so you can feel supported throughout the process. While the financial considerations are important, we are committed to helping you find the best solution for your needs.
Stem cell therapy for MS offers promising potential, but it’s important to consider its limitations. At Stemedix, we focus on providing personalized consultations to help patients navigate the decision-making process. We assist in evaluating the benefits and drawbacks of stem cell therapy based on each patient’s individual needs.
The Stemedix Approach to Stem Cell Therapy for MS
At Stemedix, based in Saint Petersburg, FL, we recognize that multiple sclerosis (MS) is a complex condition that affects each person in unique ways. This is why we prioritize personalized care to help MS patients achieve the best possible results from stem cell therapy. Our approach is tailored specifically to each patient’s needs, ensuring that every aspect of the treatment process aligns with their individual health goals and circumstances. Below, we’ll explain how Stemedix provides specialized care for MS patients through stem cell therapy.
Personalized Treatment Plans
At Stemedix, we understand that every patient’s experience with MS is unique. That’s why we prioritize personalized treatment plans tailored to your condition, medical history, and treatment goals. During your initial consultation, we gather important information about your MS progression, symptoms, and other relevant health factors. This helps us design a treatment plan that directly addresses your needs, increasing the likelihood of a successful outcome. Whether your goal is to improve mobility, reduce symptoms such as numbness, or slow disease progression, we collaborate with you to create a plan that best supports your journey.
How Stemedix Supports Patients Through Their Journey
Stem cell therapy for MS can be a complex process, and it may feel overwhelming for some patients. At Stemedix, we are dedicated to guiding you through each step of the treatment. Our team provides thorough logistical support to help you access the care you need. If you’re traveling from out of town, we assist with travel arrangements, accommodations, and other services, making your visit as seamless and stress-free as possible. We want you to focus on your health and treatment, not on the logistics of your journey.
Beyond logistical support, our experienced care coordinators are always available to assist you throughout the therapy process. They can answer your questions, offer updates on your treatment progress, and address any concerns that arise during your recovery. This level of personalized care helps you feel informed, supported, and confident as you move forward with your stem cell therapy for MS.
At Stemedix, we focus on providing patient-centered care, combining advanced stem cell treatments with compassionate support. Our tailored treatment plans and dedicated assistance are designed to help improve your quality of life while managing the symptoms and progression of multiple sclerosis.
Stemedix: A New Path to Managing Multiple Sclerosis
Stem cell therapy for multiple sclerosis (MS) presents a promising approach for managing symptoms and potentially slowing disease progression. While it is not a cure, early research suggests that this therapy could greatly improve the quality of life for those with MS. The goal of stem cell treatments is to repair nerve damage and help regulate the immune system, providing relief from symptoms such as muscle weakness, fatigue, and cognitive issues. It may also offer hope for those noticing early warning signs of multiple sclerosis, helping to slow the progression of the disease.
If you’re considering stem cell therapy for MS, it’s essential to consult with a healthcare provider to determine if it’s the right treatment for you. At Stemedix, we provide personalized consultations and tailored treatment plans that focus on your unique needs, ensuring you receive the best care possible.
To learn more about your treatment options and understand how stem cell therapy can help you manage MS, contact us at (727) 456-8968 or email at yourjourney@stemedix.com. Our team is here to support you every step of the way on your path to better health.
Spinal cord injuries (SCI) are life-altering conditions with limited treatment options. While rehabilitation and medical management can provide some improvements, regenerative medicine is emerging as a promising alternative. The CELLTOP study, an on-going multidisciplinary phase 1 study conducted at the Mayo Clinic, is investigating the safety and efficacy of adipose tissue–derived mesenchymal stem cells (AD-MSCs) to aid in spinal cord recovery.
In this initial report, Bydon et al. describe the outcome of the study’s first treated patient – a 53-year-old survivor of a surfing accident who sustained a high cervical American Spinal Injury Association Impairment Scale grade A SCI with subsequent neurologic improvement that plateaued within 6 months following injury.
The CELLTOP Trial Stem Cell Treatment Process
Nine months after his injury, the patient enrolled in the CELLTOP study. An abdominal fat tissue sample was collected, and stem cells were isolated, expanded, and preserved. Eleven months after the injury, the patient received an injection of 100 million AD-MSCs through a lumbar puncture at the L3-4 level.
Safety and Tolerability: Minimal Side Effects Observed in Trial
According to the authors, the procedure was well tolerated. The only reported side effect was a mild to moderate headache on the second day, which resolved with over-the-counter medication. No severe adverse effects were observed during the 18-month follow-up.
Observed Neurological Improvements
Following the stem cell injection, the patient showed notable improvements in motor and sensory function over 18 months, including:
Motor Function: The patient’s upper limb motor scores improved from 35 at baseline to 44 at 18 months. Lower limb motor scores increased from 36 to 49. These improvements were observed in both sides of the body.
Sensory Function: Sensation, measured through pinprick and light touch scores, nearly doubled. The pinprick score increased from 45 to 95, and the light touch score improved from 54 to 96.
Upper Extremity Capabilities: The patient’s ability to use his arms and hands improved significantly, particularly in tasks requiring pulling, pushing, and finger dexterity.
Quality of Life: The patient’s physical and mental health scores improved, as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire.
Observed Improvements in Physical Therapy Performance
Over the 18-month follow-up, the patient also demonstrated significant progress in mobility and strength, including:
His walking speed improved from 0.17 m/s to 0.43 m/s.
Walking distance increased from 635 feet in 12.8 minutes to 2200 feet in 34 minutes.
Shoulder flexibility improved, with greater range of motion in both arms.
Grip strength and hand dexterity showed notable gains.
How Stem Cells Aid in Spinal Cord Repair
SCI leads to significant nerve damage and scarring that inhibit natural healing. Stem cells offer potential benefits by:
Reducing Inflammation: AD-MSCs have anti-inflammatory properties that may create a more favorable environment for nerve regeneration.
Promoting Tissue Repair: These cells can support the growth of new nerve cells and blood vessels, enhancing recovery.
Enhancing Neuroprotection: Stem cells may help preserve existing nerve function and prevent further deterioration.
Future Prospects of Regenerative Medicine for SCI
While this case study presents promising results, further research is necessary. The CELLTOP study continues to evaluate the effectiveness of stem cell therapy in more patients. Future related studies will explore optimal dosing, timing, and potential combination therapies to enhance recovery further.
Based on these initial results, the authors conclude that regenerative medicine -particularly stem cell therapy – holds significant promise for treating SCI. The first patient in the CELLTOP study demonstrated meaningful neurological improvements, suggesting that AD-MSC therapy could offer new hope for those with SCI. Continued research and clinical trials will determine whether this treatment can become a standard option for spinal cord injury recovery.
Source: Bydon M, Dietz AB, Goncalves S, Moinuddin FM, Alvi MA, Goyal A, Yolcu Y, Hunt CL, Garlanger KL, Del Fabro AS, Reeves RK, Terzic A, Windebank AJ, Qu W. CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. Mayo Clin Proc. 2020 Feb;95(2):406-414. doi: 10.1016/j.mayocp.2019.10.008. Epub 2019 Nov 27. PMID: 31785831.
Alcoholic liver disease (ALD) is a serious global health problem that arises from chronic or binge alcohol consumption. As a chronic liver disease, ALD occurs due to alcohol’s harmful effects on the liver, which is the first organ to metabolize alcohol. This process leads to the production of harmful byproducts that damage liver cells and cause oxidative stress. Over time, this damage triggers inflammation and fibrosis (scarring of the liver), eventually progressing to conditions such as steatosis (fatty liver), steatohepatitis (inflammation and fat accumulation), cirrhosis, and even hepatocellular carcinoma (HCC), a type of liver cancer.
Despite the growing need for effective treatment options, there are currently no FDA-approved therapies specifically for ALD. The only definitive treatments available are alcohol abstinence and liver transplantation, but these options are not always accessible or feasible for all patients. Given the limitations of current treatment options, there is a pressing need for new therapeutic strategies to combat ALD.
Challenges in Current Treatment Approaches
To date, the treatments for ALD primarily focus on managing the symptoms and delaying disease progression until a liver transplant is possible. These supportive therapies aim to reduce oxidative stress, regenerate liver cells, and control inflammation. However, they are not effective for many patients.
Various drugs have been investigated to target the underlying causes of ALD, such as oxidative stress and inflammation. Despite showing promise in preclinical studies, many of these therapies have failed to demonstrate significant benefits in clinical trials. The complexity of ALD and the fact that it often develops alongside other health issues, such as poor nutrition or hepatitis, make it difficult to find a one-size-fits-all solution.
Stem Cell Therapy: A Promising Option
In recent years, stem cell therapy has emerged as a potential treatment for ALD. Among the different types of stem cells, mesenchymal stem cells (MSCs) have shown the most promise due to their ability to regenerate damaged tissue and modulate immune responses. MSCs can be sourced from various tissues such as bone marrow, adipose tissue, and umbilical cord blood. Importantly, the use of MSCs is free from the ethical concerns associated with embryonic stem cells, making them a more attractive option for therapeutic research.
MSCs have been widely studied in the context of liver diseases, including ALD, and have shown positive results in preclinical and clinical trials. These stem cells work by reducing inflammation, promoting liver cell regeneration, and improving overall liver function. Moreover, MSCs secrete factors that contribute to their therapeutic effects. These factors, known as the secretome, contain cytokines, growth factors, and extracellular vesicles (EVs), which can mimic the healing properties of MSCs themselves.
Potential for Cell-Free Therapies
Given the challenges with direct stem cell transplantation, researchers are exploring cell-free approaches, which use the secretome and EVs derived from MSCs. These cell-free therapies could offer many of the same benefits as stem cell therapy without the risks associated with cell transplantation. For instance, the secretome contains anti-inflammatory molecules and other agents that can help regenerate damaged liver tissue, while EVs carry proteins and genetic material that help reduce liver damage.
Several preclinical studies have shown that MSC-derived secretomes and EVs can alleviate the symptoms of liver diseases similar to ALD by reducing oxidative stress and inflammation. However, more research is needed to determine the optimal methods for isolating and administering these factors in a clinical setting. One of the key obstacles is the difficulty in distinguishing between EVs and other natural components in the body, making it challenging to ensure that the right therapeutic agents are delivered to patients.
Current Research and Future Directions
Although MSC-based therapies are still in the early stages of development for ALD, the research to date has been encouraging. Studies in animal models have demonstrated that MSCs and their secreted factors can reduce inflammation, prevent fibrosis, and promote liver regeneration. For example, transplantation of MSCs has been shown to improve liver function in mice with alcohol-induced liver damage, while MSC-derived EVs have been found to enhance liver regeneration by promoting the growth of new liver cells.
Stem Cell Therapy: A Promising Future for Alcoholic Liver Disease
Alcoholic liver disease is a major global health issue, with alcohol consumption contributing to a range of liver disorders that can lead to severe and life-threatening conditions. While current treatment options are limited, advances in stem cell therapy, particularly the use of mesenchymal stem cells, offer new hope for treating ALD. MSCs and their secreted factors have shown potential to reduce liver damage, promote regeneration, and modulate the immune system, making them a promising therapeutic option for ALD.
However, despite the progress in preclinical studies, Han et al. highlight many challenges to overcome before these therapies can be widely adopted in clinical practice. Further research is needed to better understand how MSCs and their secretome work, and to develop safer, more effective treatments for ALD. In the meantime, addressing the root causes of ALD, such as excessive alcohol consumption, remains crucial to reducing the burden of this disease worldwide. With continued research and innovation, MSC-based therapies may one day offer a viable solution for patients suffering from this debilitating condition.
Source: Han J, Lee C, Hur J, Jung Y. Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease. Cells. 2023; 12(1):22. https://doi.org/10.3390/cells12010022
Multiple sclerosis (MS) is a chronic disease that affects the central nervous system, leading to a range of physical and cognitive impairments. There are different types of MS, with the most common being relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS). RRMS is primarily an inflammatory condition, while SPMS involves a progressive decline due to neurodegeneration.
While significant advancements have been made in treating RRMS with new medications that target inflammation, treatment options for SPMS remain limited.
In this study, Fernández et al. aimed to evaluate the safety and feasibility of using adipose-derived mesenchymal stem cells (AdMSCs) in patients with SPMS.
Investigating Stem Cell Therapy for SPMS
Currently, the only approved treatments for SPMS with disease activity are interferon β and mitoxantrone, but their effectiveness is either uncertain or associated with serious side effects. Ocrelizumab has recently been approved for treating PPMS, but effective treatments for SPMS are still lacking.
Recently, stem cells have shown promise in various medical applications, particularly in regenerating damaged tissues and modulating the immune system. Currently, stem cell treatments are approved for conditions like blood disorders and severe burns, but mesenchymal stem cells (MSCs) are still being investigated for other uses.
Fernandez et al.’s study was conducted in two hospitals in Spain and involved a placebo-controlled, randomized trial. Patients were divided into three groups: one receiving a placebo, another receiving a lower dose of stem cells, and the third receiving a higher dose. To ensure unbiased results, the study was triple-blinded, meaning neither the patients, treating physicians, nor the statisticians analyzing the data knew which treatment each patient received.
The study also required participants to provide 30 grams of adipose tissue for stem cell preparation. Once enrolled, patients received their assigned treatment and were monitored for a year with follow-up visits at 30 days, six months, and twelve months after treatment.
Study Results and Safety Evaluation
A total of 34 patients were initially enrolled in the study. However, four patients were excluded before receiving the treatment due to abnormalities in their stem cell samples. The remaining 30 patients completed the study, with 29 undergoing at least one follow-up assessment. Unfortunately, two patients in the placebo group passed away during the trial—neither death was linked to the stem cell treatment.
Throughout the study, 70 adverse events were reported among 22 patients, with the most common being urinary infections, respiratory infections, and anemia. Four serious adverse events occurred, but only one (a urinary infection) was in a patient who received stem cells.
Overall, the authors report that there were no major safety concerns related to the treatment.
Evaluating the Effectiveness of Stem Cell Therapy
To determine whether stem cell therapy had any effect on disease progression, the authors also analyzed various clinical measures, including the Expanded Disability Status Scale (EDSS), MRI scans, and evoked potentials (tests measuring nerve function).
At the end of the 12-month follow-up, no significant differences were found between the placebo and treatment groups in terms of disability progression. The EDSS scores remained relatively stable in all groups, and MRI scans showed no significant reduction in active lesions or brain volume loss compared to placebo.
Fernández et al. report some positive trends in nerve function tests, particularly in visual evoked potentials, which measure the brain’s response to visual stimuli. Some patients in the treatment groups showed improvements in the speed of their nerve signals, suggesting possible stabilization or mild improvement. However, these changes were not statistically significant when compared to the placebo group.
AdMSC Therapy in SPMS: Findings, Challenges, and Future Directions
This study provides valuable insights into the safety of using AdMSCs in SPMS patients. The treatment was well tolerated, with no major safety concerns.
While there were some encouraging trends in nerve function, Fernández et al. call for larger and longer-term studies to determine whether these changes translate into meaningful clinical benefits. Considering this, the authors call for future research focusing on optimizing stem cell delivery methods, exploring combination therapies, and identifying patient subgroups that may benefit the most from stem cell treatments.
Source: Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, et al. (2018) Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE 13(5): e0195891. https://doi.org/10.1371/journal.pone.0195891
Progressive multiple sclerosis (PMS) is a complex, disabling form of multiple sclerosis characterized by the progressive accumulation of central nervous system (CNS) damage. This damage arises from chronic inflammation, demyelination, axonal injury, neuronal degeneration, and gliosis, affecting both white and gray matter in the brain and spinal cord. Despite advancements in MS research, effective reparative therapies for reversing the functional impairments associated with PMS remain largely unavailable.
A promising new approach for PMS treatment is NurOwn, a therapy based on mesenchymal stem cell-derived neurotrophic factor (MSC-NTF) cells. NurOwn utilizes a proprietary method to isolate and culture autologous (self-derived) mesenchymal stem cells (MSCs) from bone marrow. These MSCs are then differentiated to secrete high levels of neurotrophic factors (NTFs), which are believed to have both neuroprotective and immunomodulatory properties. Preclinical studies and early clinical trials have suggested that MSC-NTF therapy could help reduce CNS inflammation and promote neuronal repair mechanisms in PMS patients.
Cohen et al.’s open-label phase II study was conducted to evaluate safety/efficacy of three intrathecal cell treatments
Safety and Tolerability of MSC-NTF Therapy
In this Phase II clinical trial (BCT-101), the safety of MSC-NTF therapy was evaluated in 20 participants with PMS, of whom 18 received treatment. While most participants tolerated the therapy well, two discontinued due to adverse events related to the procedure, including mild symptoms such as coldness, muscle weakness, and fever, as well as one case of arachnoiditis -a rare inflammation of the arachnoid membrane surrounding the spinal cord.
For both affected individuals, MRI scans revealed characteristic lumbar nerve root clumping. Treatment with epidural cortisone and analgesics provided symptom relief, with one participant’s symptoms resolving fully. Importantly, there were no recorded deaths or adverse events associated with MS relapses, and no clinically significant alterations were observed in blood, urinalysis, or vital sign parameters after dosing.
According to the authors, these results highlight the potential tolerability of MSC-NTF therapy, though further studies are required to assess long-term safety.
Potential of MSC-NTF Therapy for PMS
NurOwn’s MSC-NTF cells have been tested in animal models relevant to PMS, including studies on autoimmune encephalomyelitis and optic nerve damage, which have shown the therapy’s potential to reduce inflammation and support neuroprotective mechanisms.
Current studies suggest that intrathecal (spinal) administration may offer unique benefits over intravenous administration by directly addressing meningeal inflammation and delivering neurotrophic factors close to the site of CNS damage. The capability of MSC-NTF cells to modulate inflammation and potentially promote endogenous repair makes it a promising therapeutic modality in PMS.
Functional and Biomarker Outcomes
Cohen et al.’s phase II study used several functional outcomes to assess MSC-NTF efficacy in PMS, including the timed 25-foot walk test (T25FW), nine-hole peg test (9-HPT), low-contrast letter acuity (LCLA), and symbol digit modalities test (SDMT).
Results indicated positive trends in these measures, suggesting that MSC-NTF therapy could improve mobility, hand function, and cognitive speed in PMS patients. Additionally, patient-reported outcomes, such as the MS Walking Scale-12 (MSWS-12), demonstrated improvements in walking function.
Biomarker analysis revealed reductions in cerebrospinal fluid (CSF) inflammatory markers, including MCP-1, sCD27, SDF-1, and osteopontin, indicating a decrease in CNS inflammation. Neuroprotective biomarkers, such as VEGF-A, HGF, NCAM1, and LIF, also showed consistent increases, suggesting that MSC-NTF cells might help support neuronal health and function in PMS. However, changes in neurodegenerative biomarkers, such as neurofilament light chain (NfL), were inconsistent, indicating the need for additional research to understand MSC-NTF’s impact on neuronal damage markers.
Insights and Future Directions Of MSC-NTF Therapy for PMS
This open-label, single-arm Phase II study demonstrated that MSC-NTF cells could be safely administered in participants with stable, non-relapsing PMS. Although two participants experienced arachnoiditis following intrathecal treatment, the majority tolerated the therapy well. Functional outcomes showed encouraging trends, suggesting possible benefits of MSC-NTF therapy in improving physical and cognitive function in PMS patients.
The study also highlighted several limitations, including the lack of a placebo-controlled group, which may introduce bias in interpreting efficacy results, and limitations in biomarker analysis due to sample timing. Additionally, inconsistent changes in neurodegenerative biomarkers and the small sample size warrant further investigation.
In summary, this Phase II trial provides preliminary evidence supporting the safety and potential therapeutic benefits of MSC-NTF cell therapy in PMS. While these initial findings are promising, larger placebo-controlled studies are needed to confirm efficacy and further elucidate the role of MSC-NTF cells in modulating CNS inflammation and promoting neuroprotection in PMS.
Source: Cohen JA, Lublin FD, Lock C, et al. Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Multiple Sclerosis Journal. 2023;29(1):92-106. doi:10.1177/13524585221122156
Back pain is the most common cause of disability worldwide, impacting people of all ages and socioeconomic backgrounds. In North America, it is one of the top reasons people miss work and visit doctors. Studies show that at least 80% of Americans will experience low back pain at some point in their lives, making it a major contributor to healthcare costs and lost income, amounting to over $50 billion each year. Although various factors can cause back pain, most cases are mechanical rather than due to an underlying disease. One of the main sources of chronic back pain is the degeneration of intervertebral discs, which can lead to pain in the lower back and neck. Despite its prevalence, there is no standard treatment that effectively restores the normal function of these degenerated discs.
Understanding Disc Degeneration and Back Pain
Degenerative disc disease is one of the most significant contributors to chronic low back pain. As intervertebral discs age or become damaged, they lose their ability to cushion the spine, causing pain and reduced mobility. Degeneration can occur naturally due to aging, but other factors like injury or genetic predisposition can also accelerate the process. While imaging tests such as MRIs can identify disc degeneration, they don’t always pinpoint the exact cause of the pain. This makes treating degenerative disc disease challenging, as doctors struggle to find therapies that not only alleviate pain but also restore disc health.
Emerging Stem Cell Therapies for Back Pain
Recently, regenerative medicine, particularly stem cell therapy, has gained attention as a potential treatment for degenerative disc disease. Stem cells have the ability to transform into different types of cells, making them suitable for repairing damaged tissues. In theory, injecting stem cells into degenerated discs could help regenerate disc tissue and reduce pain.
Overview of Clinical Studies
Several clinical studies have examined the potential of stem cell therapies for treating degenerative disc disease, with mixed results. The types of stem cells studied include:
Autologous mesenchymal stem cells (MSCs): These are derived from a patient’s own body, often from bone marrow or fat tissue. Some studies reported a reduction in pain and improvement in quality of life following treatment with MSCs. However, results were inconsistent, and improvements did not always correspond to measurable changes in the disc’s structure.
Allogenic stem cells: These are stem cells from donors’ umbilical cord tissue. Research on allogenic stem cells is still limited, with few studies showing significant long-term benefits.
Chondrocytes: These cells, which produce cartilage, have also been used in some studies to promote disc regeneration. However, there is limited evidence supporting their use, and more research is needed.
Overall, the studies reviewed had varying degrees of success, with some patients experiencing significant pain relief and others seeing little to no improvement. Many studies lacked control groups or were not randomized, making it difficult to draw definitive conclusions. The most common outcomes measured were pain scores and functional improvements, but there was no clear evidence that stem cell therapy restored the physical structure of degenerated discs.
How Stem Cells Might Work
There are several theories about how stem cells could help regenerate damaged discs. One possibility is that stem cells differentiate into the type of cells needed to repair the disc, such as cells that produce cartilage or other supportive tissues. Another theory is that stem cells create a supportive environment that encourages the body’s own repair mechanisms. For example, animal studies have shown that stem cells can increase the production of molecules that help repair and strengthen disc tissue.
The Future of Stem Cell Therapy for Back Pain
Soufi et al. report that stem cell therapy remains a promising area of research for treating degenerative disc disease. Ongoing clinical trials aim to establish the safety and effectiveness of these treatments in humans, and if successful, could pave the way for a new approach to managing chronic back pain. For stem cell therapy to become a standard treatment, more studies are needed to identify which patients are most likely to benefit and to optimize treatment protocols, including the type and dosage of stem cells.
Researchers are also exploring the use of tissue-engineering technologies and biomaterials to enhance the effectiveness of stem cell therapies. Combining stem cells with supportive scaffolds could improve the chances of successful disc regeneration and provide a more stable environment for cell growth.
The Potential of Stem Cell Therapy for Degenerative Disc Disease and Back Pain
Back pain, particularly when related to degenerative disc disease, is a significant health issue with limited effective treatment options. Stem cell therapy represents a new frontier in regenerative medicine, with the potential to offer relief to patients who have not responded to traditional therapies.
Source: Soufi, K.H.; Castillo, J.A.; Rogdriguez, F.Y.; DeMesa, C.J.; Ebinu, J.O. Potential Role for Stem Cell Regenerative Therapy as a Treatment for Degenerative Disc Disease and Low Back Pain: A Systematic Review. Int. J. Mol. Sci.2023, 24, 8893. https://doi.org/10.3390/ijms24108893
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Subscribe To Our Newsletter
Join our mailing list to receive the latest news and updates from our team.
You have Successfully Subscribed!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
St. Petersburg, Florida
